{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T02:59:31Z","timestamp":1787626771486,"version":"build-2736575974"},"reference-count":62,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100013129","name":"Ministry of SMEs and Startups","doi-asserted-by":"publisher","award":["S2883658"],"award-info":[{"award-number":["S2883658"]}],"id":[{"id":"10.13039\/501100013129","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002536","name":"Mokpo National University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002536","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003621","name":"Ministry of Science, ICT and Future Planning","doi-asserted-by":"publisher","award":["2022R1A5A8033794"],"award-info":[{"award-number":["2022R1A5A8033794"]}],"id":[{"id":"10.13039\/501100003621","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.jconrel.2022.07.012","type":"journal-article","created":{"date-parts":[[2022,7,19]],"date-time":"2022-07-19T19:38:49Z","timestamp":1658259529000},"page":"502-519","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["Enhanced oral absorption of teriparatide with therapeutic potential for management of osteoporosis"],"prefix":"10.1016","volume":"349","author":[{"given":"Laxman","family":"Subedi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prashant","family":"Pandey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seo Hee","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ki-Taek","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung-Sik","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwan-Young","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youngro","family":"Byun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung-Hyun","family":"Shim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin Woo","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2022.07.012_bb0005","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s00774-014-0586-6","article-title":"Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of the Japanese Society for Bone and Mineral Research: 2014 update","volume":"32","author":"Suzuki","year":"2014","journal-title":"J. Bone Miner. Metab."},{"key":"10.1016\/j.jconrel.2022.07.012_bb0010","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/S8756-3282(01)00414-8","article-title":"Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles","volume":"28","author":"Mashiba","year":"2001","journal-title":"Bone"},{"key":"10.1016\/j.jconrel.2022.07.012_bb0015","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.bone.2007.04.198","article-title":"Low bone mineral density is associated with bone microdamage accumulation in postmenopausal women with osteoporosis","volume":"41","author":"Stepan","year":"2007","journal-title":"Bone"},{"key":"10.1016\/j.jconrel.2022.07.012_bb0020","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1056\/NEJMoa023110","article-title":"Bisphosphonate-induced osteopetrosis","volume":"349","author":"Whyte","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2022.07.012_bb0025","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1177\/1759720X13477714","article-title":"Bisphosphonate drug holiday: who, when and how long","volume":"5","author":"Diab","year":"2013","journal-title":"Ther. Adv. Musculoskelet Dis."},{"key":"10.1016\/j.jconrel.2022.07.012_bb0030","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S8756-3282(98)00167-7","article-title":"Parathyroid hormone stimulates cancellous bone formation at skeletal sites regardless of marrow composition in ovariectomized rats","volume":"24","author":"Li","year":"1999","journal-title":"Bone"},{"key":"10.1016\/j.jconrel.2022.07.012_bb0035","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/8756-3282(94)00033-V","article-title":"The anabolic effects of parathyroid hormone on cortical bone mass, dimensions and strength\u2014assessed in a sexually mature, ovariectomized rat model","volume":"16","author":"Mosekilde","year":"1995","journal-title":"Bone"},{"key":"10.1016\/j.jconrel.2022.07.012_bb0040","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1359\/jbmr.1997.12.3.384","article-title":"An intact N terminus is required for the anabolic action of parathyroid hormone on adult female rats","volume":"12","author":"Armamento-Villareal","year":"1997","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.jconrel.2022.07.012_bb0045","first-page":"2739","article-title":"Comparison of the biochemical responses to human parathyroid hormone-(1\u221231)NH2 and hPTH-(1-34) in healthy humans","volume":"84","author":"Fraher","year":"1999","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.jconrel.2022.07.012_bb0050","doi-asserted-by":"crossref","first-page":"617","DOI":"10.2131\/jts.37.617","article-title":"Osteosarcoma in Sprague-Dawley rats after long-term treatment with teriparatide (human parathyroid hormone (1-34))","volume":"37","author":"Watanabe","year":"2012","journal-title":"J. Toxicol. Sci."},{"key":"10.1016\/j.jconrel.2022.07.012_bb0055","doi-asserted-by":"crossref","first-page":"435","DOI":"10.2131\/jts.43.435","article-title":"Effect of dosing frequency of teriparatide (PTH 1-34) on bone formation in rats: comparison of bone metabolism marker levels","volume":"43","author":"Watanabe","year":"2018","journal-title":"J. Toxicol. Sci."},{"key":"10.1016\/j.jconrel.2022.07.012_bb0060","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0168-3659(96)01586-6","article-title":"The challenge of proteolytic enzymes in intestinal peptide delivery","volume":"46","author":"Langguth","year":"1997","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2022.07.012_bb0065","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1208\/s12248-014-9688-2","article-title":"Physicochemical and formulation developability assessment for therapeutic peptide delivery\u2014a primer","volume":"17","author":"Bak","year":"2015","journal-title":"AAPS J."},{"key":"10.1016\/j.jconrel.2022.07.012_bb0070","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.ejps.2010.01.006","article-title":"Lyophilization of water-in-oil emulsions to prepare phospholipid-based anhydrous reverse micelles for oral peptide delivery","volume":"39","author":"Wang","year":"2010","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2022.07.012_bb0075","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S0928-0987(00)00167-6","article-title":"Lipid formulations for oral administration of drugs: non-emulsifying, self-emulsifying and \u2018self-microemulsifying\u2019drug delivery systems","volume":"11","author":"Pouton","year":"2000","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2022.07.012_bb0080","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.addr.2007.09.006","article-title":"Approaches for the development of solid and semi-solid lipid-based formulations","volume":"60","author":"Jannin","year":"2008","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2022.07.012_bb0085","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1016\/j.actbio.2012.03.015","article-title":"Sustained release of PTH (1\u201334) from PLGA microspheres suppresses osteoarthritis progression in rats","volume":"8","author":"Eswaramoorthy","year":"2012","journal-title":"Acta Biomater."},{"key":"10.1016\/j.jconrel.2022.07.012_bb0090","doi-asserted-by":"crossref","first-page":"362","DOI":"10.3109\/03639040903173580","article-title":"Evaluation of salmon calcitonin (sCT) enteric-coated capsule for enhanced absorption and GI tolerability in rats","volume":"36","author":"Wu","year":"2010","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.jconrel.2022.07.012_bb0095","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1023\/A:1016488623022","article-title":"Mucoadhesive polymers in peroral peptide drug delivery. VI. Carbomer and chitosan improve the intestinal absorption of the peptide drug buserelin in vivo","volume":"13","author":"Luessen","year":"1996","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2022.07.012_bb0100","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.ijpharm.2004.12.017","article-title":"Improvement of absorption enhancing effects of n-dodecyl-\u03b2-D-maltopyranoside by its colon-specific delivery using chitosan capsules","volume":"293","author":"Fetih","year":"2005","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2022.07.012_bb0105","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.addr.2016.06.005","article-title":"Intestinal permeation enhancers for oral peptide delivery","volume":"106","author":"Maher","year":"2016","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2022.07.012_bb0110","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.ijpharm.2011.08.029","article-title":"Preliminary evaluation of a novel oral delivery system for rhPTH1-34: in vitro and in vivo","volume":"420","author":"Guo","year":"2011","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2022.07.012_bb0115","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1023\/A:1010936227570","article-title":"Oral delivery of biologically active parathyroid hormone","volume":"18","author":"Leone-Bay","year":"2001","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2022.07.012_bb0120","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1021\/mp900319k","article-title":"Anticoagulant efficacy of solid oral formulations containing a new heparin derivative","volume":"7","author":"Park","year":"2010","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2022.07.012_bb0125","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/BF01960074","article-title":"Ion pair absorption of ionized drugs\u2014fact or fiction?","volume":"5","author":"Jonkman","year":"1983","journal-title":"Pharma Weekbl Sci."},{"key":"10.1016\/j.jconrel.2022.07.012_bb0130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejps.2015.11.004","article-title":"Oral delivery of zoledronic acid by non-covalent conjugation with lysine-deoxycholic acid: in vitro characterization and in vivo anti-osteoporotic efficacy in ovariectomized rats","volume":"82","author":"Jeon","year":"2016","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2022.07.012_bb0135","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1128\/AAC.50.5.1869-1871.2006","article-title":"Pharmacokinetics of a new, orally available ceftriaxone formulation in physical complexation with a cationic analogue of bile acid in rats","volume":"50","author":"Lee","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jconrel.2022.07.012_bb0140","doi-asserted-by":"crossref","first-page":"6379","DOI":"10.2147\/IJN.S121114","article-title":"Multiple nanoemulsion system for an oral combinational delivery of oxaliplatin and 5-fluorouracil: preparation and in vivo evaluation","volume":"11","author":"Pangeni","year":"2016","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.jconrel.2022.07.012_bb0145","doi-asserted-by":"crossref","first-page":"3329","DOI":"10.2147\/IJN.S167958","article-title":"Enhanced oral absorption of pemetrexed by ion-pairing complex formation with deoxycholic acid derivative and multiple nanoemulsion formulations: preparation, characterization, and in vivo oral bioavailability and anticancer effect","volume":"13","author":"Pangeni","year":"2018","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.jconrel.2022.07.012_bb0150","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1021\/mp9002688","article-title":"Diabetes correction in pancreatectomized canines by orally absorbable insulin\u2212 deoxycholate complex","volume":"7","author":"Kim","year":"2010","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2022.07.012_bb0155","doi-asserted-by":"crossref","first-page":"705","DOI":"10.2147\/IJN.S151474","article-title":"Intranasal delivery of Huperzine a to the brain using lactoferrin-conjugated N-trimethylated chitosan surface-modified PLGA nanoparticles for treatment of Alzheimer\u2019s disease","volume":"13","author":"Meng","year":"2018","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.jconrel.2022.07.012_bb0160","doi-asserted-by":"crossref","first-page":"7719","DOI":"10.2147\/IJN.S267424","article-title":"Improvements in the oral absorption and anticancer efficacy of an oxaliplatin-loaded solid formulation: pharmacokinetic properties in rats and nonhuman primates and the effects of oral metronomic dosing on colorectal cancer","volume":"15","author":"Pangeni","year":"2020","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.jconrel.2022.07.012_bb0165","doi-asserted-by":"crossref","first-page":"4231","DOI":"10.2147\/IJN.S110573","article-title":"Preparation and in vivo evaluation of an orally available enteric-microencapsulated parathyroid hormone (1-34)-deoxycholic acid nanocomplex","volume":"11","author":"Hwang","year":"2016","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.jconrel.2022.07.012_bb0170","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1080\/10717544.2021.1995077","article-title":"Metronomic delivery of orally available pemetrexed-incorporated colloidal dispersions for boosting tumor-specific immunity","volume":"28","author":"Maharjan","year":"2021","journal-title":"Drug Deliv."},{"key":"10.1016\/j.jconrel.2022.07.012_bb0175","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1210\/endo-126-5-2327","article-title":"Biochemical and morphological characterization of parathyroid hormone receptor binding to the rat osteosarcoma cell line UMR-106","volume":"126","author":"Mitchell","year":"1990","journal-title":"Endocrinology"},{"key":"10.1016\/j.jconrel.2022.07.012_bb0180","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ejpb.2021.11.010","article-title":"Intestinal permeation enhancers enable oral delivery of macromolecules up to 70 kDa in size","volume":"170","author":"Katherine","year":"2022","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jconrel.2022.07.012_bb0185","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.jchromb.2013.08.027","article-title":"High sensitivity LC\u2013MS\/MS method for direct quantification of human parathyroid 1\u201334 (teriparatide) in human plasma","volume":"938","author":"Chambers","year":"2013","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.jconrel.2022.07.012_bb0190","doi-asserted-by":"crossref","first-page":"123046","DOI":"10.1016\/j.jchromb.2021.123046","article-title":"Bioanalytical method development and validation of highly selective and sensitive LC-MS\/MS method for determination of teriparatide (parathyroid hormone fragment 1-34) in human serum through direct detection of intact teriparatide molecule","volume":"1187","author":"Kusuma","year":"2021","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.jconrel.2022.07.012_bb0195","first-page":"20170030","article-title":"Factors affecting the physical stability (aggregation) of peptide therapeutics, Interface","volume":"7","author":"Zapadka","year":"2017","journal-title":"Focus"},{"key":"10.1016\/j.jconrel.2022.07.012_bb0200","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.ejpb.2020.04.004","article-title":"Hydrophobic ion pairing (HIP) of (poly)peptide drugs: benefits and drawbacks of different preparation methods","volume":"151","author":"Wibel","year":"2020","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jconrel.2022.07.012_bb0205","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1007\/s11481-010-9226-7","article-title":"n-Dodecyl-\u03b2-D-maltoside inhibits aggregation of human interferon-\u03b2-1b and reduces its immunogenicity","volume":"6","author":"Rifkin","year":"2011","journal-title":"J. NeuroImmune Pharmacol."},{"key":"10.1016\/j.jconrel.2022.07.012_bb0210","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1006\/bbrc.1999.1958","article-title":"Solution structures of human parathyroid hormone fragments hPTH(1-34) and hPTH(1-39) and bovine parathyroid hormone fragment bPTH(1-37)","volume":"267","author":"Marx","year":"2000","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.jconrel.2022.07.012_bb0215","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1021\/acs.jmedchem.7b00237","article-title":"How big is too big for cell permeability?","volume":"60","author":"Matsson","year":"2017","journal-title":"I Med. Chem."},{"key":"10.1016\/j.jconrel.2022.07.012_bb0220","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/0169-409X(91)90014-4","article-title":"(B) Mechanisms of peptide and protein absorption: (2) transcellular mechanism of peptide and protein absorption: passive aspects","volume":"7","author":"Burton","year":"1991","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2022.07.012_bb0225","doi-asserted-by":"crossref","first-page":"4734","DOI":"10.1021\/acs.molpharmaceut.7b00297","article-title":"Dodecylmaltoside modulates bicellular tight junction contacts to promote enhanced permeability","volume":"14","author":"Gradauer","year":"2017","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2022.07.012_bb0230","doi-asserted-by":"crossref","first-page":"6082","DOI":"10.1016\/j.biomaterials.2013.04.053","article-title":"The transport mechanisms of polymer nanoparticles in Caco-2 epithelial cells","volume":"34","author":"He","year":"2013","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2022.07.012_bb0235","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.addr.2019.04.008","article-title":"Concepts of nanoparticle cellular uptake, intracellular trafficking, and kinetics in nanomedicine","volume":"143","author":"Donahue","year":"2019","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2022.07.012_bb0240","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.biomaterials.2017.09.022","article-title":"Bile acid transporter mediated endocytosis of oral bile acid conjugated nanocomplex","volume":"147","author":"Park","year":"2017","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2022.07.012_bb0245","doi-asserted-by":"crossref","first-page":"2694","DOI":"10.1039\/C8SM00274F","article-title":"Prediction of striped cylindrical micelles (SCMs) formed by dodecyl-\u03b2-d-maltoside (DDM) surfactants","volume":"14","author":"Mandal","year":"2018","journal-title":"Soft Matter"},{"key":"10.1016\/j.jconrel.2022.07.012_bb0250","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1089\/jir.2013.0131","article-title":"The effects of dodecyl maltoside and sodium dodecyl sulfate surfactants on the stability and aggregation of recombinant interferon Beta-1b","volume":"34","author":"Haji Abdolvahab","year":"2014","journal-title":"J. Interf. Cytokine Res."},{"key":"10.1016\/j.jconrel.2022.07.012_bb0255","first-page":"562","article-title":"Protein\u2013surfactant interactions: a tale of many states","volume":"2011","author":"Otzen","year":"1814","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.jconrel.2022.07.012_bb0260","doi-asserted-by":"crossref","first-page":"145","DOI":"10.3109\/10717541003604882","article-title":"Effect of dodecylmaltoside (DDM) on uptake of BCS III compounds, tiludronate and cromolyn, in Caco-2 cells and rat intestine model","volume":"17","author":"Deshmukh","year":"2010","journal-title":"Drug Deliv."},{"key":"10.1016\/j.jconrel.2022.07.012_bb0265","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1152\/ajpgi.00043.2007","article-title":"Bile acids modulate tight junction structure and barrier function of Caco-2 monolayers via EGFR activation","volume":"294","author":"Raimondi","year":"2008","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"10.1016\/j.jconrel.2022.07.012_bb0270","doi-asserted-by":"crossref","first-page":"107539","DOI":"10.1016\/j.pharmthera.2020.107539","article-title":"Apical sodium-dependent bile acid transporter, drug target for bile acid related diseases and delivery target for prodrugs: current and future challenges","volume":"212","author":"Li","year":"2020","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.jconrel.2022.07.012_bb0275","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.jconrel.2020.07.034","article-title":"Bile acid transporter-mediated oral drug delivery","volume":"327","author":"Deng","year":"2020","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2022.07.012_bb0280","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1039\/C0CS00003E","article-title":"Strategies for the intracellular delivery of nanoparticles","volume":"40","author":"Chou","year":"2011","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.jconrel.2022.07.012_bb0285","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1016\/j.drudis.2016.04.007","article-title":"Intracellular transport of nanocarriers across the intestinal epithelium","volume":"21","author":"Fan","year":"2016","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.jconrel.2022.07.012_bb0290","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1111\/j.1600-0854.2011.01188.x","article-title":"Physiology and pathology of endosome-to-Golgi retrograde sorting","volume":"12","author":"Burd","year":"2011","journal-title":"Traffic"},{"key":"10.1016\/j.jconrel.2022.07.012_bb0295","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/S8756-3282(00)00355-0","article-title":"Comparison of bone formation responses to parathyroid hormone (1-34), (1-31), and (2-34) in mice","volume":"27","author":"Mohan","year":"2000","journal-title":"Bone"},{"key":"10.1016\/j.jconrel.2022.07.012_bb0300","first-page":"20","article-title":"Glucocorticoid-induced osteoporosis: who to treat with what agent?","volume":"8","author":"Rizzoli","year":"2016","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.jconrel.2022.07.012_bb0305","doi-asserted-by":"crossref","first-page":"3485","DOI":"10.1002\/art.23954","article-title":"Glucocorticoid-induced bone loss in mice can be reversed by the actions of parathyroid hormone and risedronate on different pathways for bone formation and mineralization","volume":"58","author":"Yao","year":"2008","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jconrel.2022.07.012_bb0310","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1007\/s00223-009-9301-3","article-title":"Glucocorticoid-induced osteoporosis in growing mice is not prevented by simultaneous intermittent PTH treatment","volume":"85","author":"Postnov","year":"2009","journal-title":"Calcif. Tissue Int."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365922004229?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365922004229?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T16:28:52Z","timestamp":1759163332000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365922004229"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":62,"alternative-id":["S0168365922004229"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2022.07.012","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Enhanced oral absorption of teriparatide with therapeutic potential for management of osteoporosis","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2022.07.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}